Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Gynecologic 5Gastrointestinal 4Thoracic 3Head & Neck 3Tumor-Agnostic 2Genitourinary 2Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Anemia 1

Interventions

Cyclophosphamide 94fludarabine phosphate 87Busulfan 64Cyclosporine 57Epoetin Alfa 55Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53fludarabine 45Antilymphocyte Serum 43Filgrastim 41Cytarabine 41Melphalan 40Tacrolimus 39Darbepoetin alfa 39Methotrexate 34Radiotherapy 33Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23apixaban 22Methylprednisolone 22Rivaroxaban 21Etoposide 21Thiotepa 17Dalteparin 17eltrombopag 16ferric carboxymaltose 14epoetin beta 14Daunorubicin 14Azacitidine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Population Groups × Classical hematology × Clear all
NCT06737081 2024-12-17

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
60 enrolled
Classical hematology

Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡